NEW
HAVEN, Conn., Jan. 6, 2023
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced
that Vlad Coric, M.D., Chairman and Chief Executive Officer,
will present at the 41st Annual J.P. Morgan
Healthcare Conference at The Westin St. Francis Hotel in
San Francisco, California, on
Tuesday, January 10, 2023 at
7:30 am (PT).
A slide deck of the presentation will be available on the
Investors section of the Biohaven website at www.biohaven.com.
About Biohaven
Biohaven is a global clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
life-changing therapies for people with debilitating neurological
and neuropsychiatric diseases, including rare disorders. The
company is advancing a pipeline of best-in-class therapies for
diseases with little or no treatment options, leveraging its proven
drug development capabilities and proprietary platforms, including
Kv7 ion channel modulation for epilepsy and neuronal
hyperexcitability; glutamate modulation for obsessive-compulsive
disorder and spinocerebellar ataxia, myostatin inhibition for
neuromuscular diseases and bispecific molecules for immune based
disorders. Biohaven's portfolio of early- and late-stage product
candidates also includes discovery research programs focused on
TRPM3 channel activation for neuropathic pain and CD-38 antibody
recruiting, bispecific molecules for multiple myeloma. More
information about Biohaven is available at www.biohaven.com.
Forward-looking
Statements
This news release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
The use of certain words, including "continue", "plan", "will",
"believe", "may", "expect", "anticipate" and similar expressions,
is intended to identify forward-looking statements. Investors are
cautioned that any forward-looking statements, including statements
regarding the future development, timing and potential marketing
approval and commercialization of development candidates are not
guarantees of future performance or results and involve substantial
risks and uncertainties. Actual results, developments and events
may differ materially from those in the forward-looking statements
as a result of various factors including: the expected timing,
commencement and outcomes of Biohaven's planned and ongoing
clinical trials; the timing of planned interactions and filings
with the Food and Drug Administration; the timing and outcome of
expected regulatory filings; complying with applicable U.S.
regulatory requirements; the potential commercialization of
Biohaven's product candidates; the potential for Biohaven's product
candidates to be first in class or best in class therapies; and the
effectiveness and safety of Biohaven's product candidates.
Additional important factors to be considered in connection with
forward-looking statements are described in Biohaven's filings with
the Securities and Exchange Commission, including within the
sections titled "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations". The
forward-looking statements are made as of the date of this new
release, and Biohaven does not undertake any obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
201-248-0741
Media Contact:
Mike
Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biohaven-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301715160.html
SOURCE BIOHAVEN LTD